Ablynx gains on RA data for vobarilizumab

Ablynx N.V. (Euronext:ABLX) gained EUR 1.42 (12%) to EUR 12.95 on Thursday after reporting 12-week data from a 251-patient Phase IIb study comparing three dosing regimens of vobarilizumab (ALX-0061) to more frequently dosed Actemra tocilizumab to treat moderately

Read the full 385 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE